FDA Reconsiders Unproven Peptides Amid Controversy

The FDA is set to reevaluate 12 peptides previously banned in 2023 due to safety concerns. There is suspicion that Robert F. Kennedy Jr. may influence the advisory board with allies who favor easing access to these drugs without rigorous scientific backing. This mirrors past actions at the CDC, where Kennedy's influence led to recommendations that aligned with his anti-vaccine stance, often contradicting scientific evidence.

The Peptides Compounding Advisory Committee (PCAC) will consider reinstating these peptides for compounding pharmacies, which create custom medication formulations. In 2023, the FDA removed these peptides from the list due to significant safety risks, emphasizing the need for standard FDA approval processes rather than lenient alternatives. Experts like Robert Steinbrook argue that without credible safety and effectiveness data, these peptides should not bypass the rigorous approval process.

The FDA will review seven peptides in July 2026, including BPC-157 and TB-500, with the remaining five scheduled for February 2027. Despite the FDA's listed uses, these peptides are often marketed online for unapproved purposes, such as tissue repair in athletic injuries, highlighting the disconnect between approved uses and public perception.